Memantine for treatment of moderate or severe Alzheimer’s disease patients in urban China: clinical and economic outcomes from a health economic model

References

• Wang W, Wu S, Cheng X, et al. Prevalence of Alzheimer’s disease and other dementing disorders in an urban community of Beijing, China. Neuroepidemiology 2000;19:194-200
   PubMed Web of Science ®Google Scholar
• Dementia in China. China Alzheimer’s Project. Available from: http://memory360.org/en/#1 [Last accessed November 2014]
   Google Scholar
• Prince M. Care arrangements for people with dementia in developing countries. Int J Geriatr Psychiatry 2004;19:170-7
   PubMed Web of Science ®Google Scholar
• Stefanacci RG. The costs of Alzheimer’s disease and the value of effective therapies. Am J Manag Care 2011;17(Suppl 13):S356-62
   PubMedGoogle Scholar
• Wang G, Cheng Q, Zhang S, et al. Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai. China. J Alzheimers Dis 2008;15:109-15
   PubMed Web of Science ®Google Scholar
• Li XL, Hu N, Tan MS, et al. Behavioral and psychological symptoms in Alzheimer’s disease. Biomed Res Int 2014;2014:927804
   PubMedGoogle Scholar
• Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002;59:1721-9
   PubMed Web of Science ®Google Scholar
• Bidzan L, Bidzan M, Pachalska M. Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia. Med Sci Monit 2012;18:Cr182-9
   PubMed Web of Science ®Google Scholar
• Cummings J, Mintzer J, Brodaty H, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr 2015;27:7-17
   PubMed Web of Science ®Google Scholar
• Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008;13:97-107
   PubMed Web of Science ®Google Scholar
• Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704-15
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-9
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333-41
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:136-43
   PubMed Web of Science ®Google Scholar
• Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-45
   PubMed Web of Science ®Google Scholar
• Livingston G, Katona C. The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004;19:919-25
   PubMedGoogle Scholar
• Antonanzas F, Rive B, Badenas JM, et al. Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: An adaptation in Spain. Eur J Health Econ 2006;7:137-44
   PubMedGoogle Scholar
• Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease : a markov model in Finland. Clin Drug Investig 2004;24:373-84
   PubMed Web of Science ®Google Scholar
• Rive B, Aarsland D, Grishchenko M, et al. Cost-effectiveness of memantine in moderate and severe Alzheimer’s disease in Norway. Int J Geriatr Psychiatry 2012;27:573-82
   Google Scholar
• Rive B, Grishchenko M, Guilhaume-Goulant C, et al. Cost effectiveness of memantine in Alzheimer’s disease in the UK. J Med Econ 2010;13:371-80
   PubMedGoogle Scholar
• Yan J, Ge L, Clay E, et al. Disease Management, Resource Utilisation and Associated Costs for Moderate and Severe Dementia Patients in China: Results From a Delphi Panel. 6th ISPOR Asia-Pacific Conference, Beijing, China; 2014
   Google Scholar
• Chen X, Zhang ZX, WX D, JL Y. Multicentre research on efficacy and tolerance of memantine in Chinese patients with Alzheimer’s disease. Chinese J Neurol 2007;40:364-8
   Google Scholar
• Wimo A, Winblad B, Stoffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics 2003;21:327-40
   PubMed Web of Science ®Google Scholar
• Bossers WJ, van der Woude LH, Boersma F, et al. Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic review. Dement Geriatr Cogn Dis Extra 2012;2:589-609
   PubMedGoogle Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14
   PubMed Web of Science ®Google Scholar
• Hong Z, Zhou B, Huang MS, et al. [Predictive factors on mortality and survival of elderly dementia in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2005;26:404-7
   Google Scholar
• National Bureau of Statistics of China: National Data. Available from: http://data.stats.gov.cn [Last accessed November 2014]
   Google Scholar
• Mould-Quevedo JF, Tang B, Harary E, et al. The burden of caring for dementia patients: caregiver reports from a cross-sectional hospital-based study in China. Expert Rev Pharmacoecon Outcomes Res 2013;13:663-73
   PubMed Web of Science ®Google Scholar
• Hu S. Pharmacoeconomic Guidelines in Asia: Focus on China Guidelines for Pharmacoeconomic Evaluations. 2011. Available from: http://ispor.org/meetings/baltimore0511/presentations/ASIAForum.pdf [Last accessed February 2015]
   Google Scholar
• Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010;51:405-14
   PubMed Web of Science ®Google Scholar
• Wu B, Wilson A, Wang FF, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in China. PLoS One 2012;7:e47373
   PubMedGoogle Scholar
• Qianqian S, Xiaocheng W, Panpan K. Trend prediction of prevalence of Alzheimer’s disease in china based on markov model. Chinese J Health Statistics 2015;32:59-62
   Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007;52:519-26
   PubMed Web of Science ®Google Scholar
• Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004;21:607-20
   PubMed Web of Science ®Google Scholar
• Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l’Assurance Maladie du Quebec database. Can J Psychiatry 2013;58:195-200
   PubMed Web of Science ®Google Scholar
• Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology 2008;31:193-200
   Google Scholar
• Zahodne LB, Ornstein K, Cosentino S, et al. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. Am J Geriatr Psychiatry 2015;23:130-40
   PubMed Web of Science ®Google Scholar
• Ryu SH, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am J Geriatr Psychiatry 2005;13:976-83
   PubMed Web of Science ®Google Scholar
• Vilalta-Franch J, Lopez-Pousa S, Calvo-Perxas L, Garre-Olmo J. Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry 2013;21:1135-43
   Google Scholar
• Chen R, Hu Z, Chen RL, et al. Determinants for undetected dementia and late-life depression. Br J Psychiatry 2013;203:203-8
   PubMed Web of Science ®Google Scholar
• Darba J, Kaskens L, Lacey L. Relationship between global severity of patients with Alzheimer’s disease and costs of care in Spain; results from the co-dependence study in Spain. Eur J Health Econ 2014. [Epub ahead of print]
   Google Scholar
• Alzheimer’s Association. 2014 Alzheimer’s disease facts and figures. Alzheimers Dement 2014;10(2):e47-92
   PubMed Web of Science ®Google Scholar
• Gillespie P, O’Shea E, Cullinan J, et al. Longitudinal costs of caring for people with Alzheimer’s disease. Int Psychogeriatr 2015;27(5):847-56
   PubMed Web of Science ®Google Scholar
• Pena-Longobardo LM, Oliva-Moreno J. Economic valuation and determinants of informal care to people with Alzheimer’s disease. Eur J Health Econ 2015;15(5):507-15
   Google Scholar
• Rattinger GB, Schwartz S, Mullins CD, et al. Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement 2015. [Epub ahead of print]
   Google Scholar
• Schaller S, Mauskopf J, Kriza C, et al. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry 2015;30(2):111-29
   Google Scholar
• Sanlin J, Xianqiang Z. The reasons and trends of increases in labour costs in China. Economic Review 2013;2:37-42
   Google Scholar
• Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health 2009;12(Suppl 3):S66-9
   PubMed Web of Science ®Google Scholar
• Low W, Azmi S, Yee SL, et al. Comparative pharmacoeconomics studies of treatment for major depressive disorder in China. Value Health 2014;17:A769
   Google Scholar
• Low W, Azmi S, Yee SL, Milea D. Health economics methodologies involving parkinson’s disease treatment in China. 6th ISPOR Asia-Pacific Conference, Beijing, China; 2014
   Google Scholar